基于MMSA-1与DKK1的新型多表位疫苗用于多发性骨髓瘤免疫治疗
研究鉴定出在多发性骨髓瘤中特异性表达的膜蛋白MMSA-1,并筛选HLA-A*0201限制性表位;将MMSA-1与DKK1表位组合构建多表位肽疫苗,在体外可诱导CTL反应,在骨髓瘤荷瘤重症联合免疫缺陷小鼠中较单表位疫苗显著提高生存率、减小肿瘤体积并减轻骨破坏。
要点
- MMSA-1在多发性骨髓瘤中特异性表达且与疾病显著正相关。
- MMSA-1表位SLSLLTIYV疫苗在体外可诱导明显的CTL反应。
- 多表位疫苗较单表位疫苗更有效裂解U266细胞并改善荷瘤小鼠生存。
核心结论
- 研究鉴定出MMSA-1的新肽段,多表位疫苗将用于为多发性骨髓瘤建立合适的个体化治疗。
研究设计与样本
- 研究鉴定肿瘤相关抗原MMSA-1并筛选HLA-A*0201限制性表位,构建MMSA-1与DKK1表位组合的多表位肽疫苗,在体外及骨髓瘤荷瘤重症联合免疫缺陷小鼠中评价。
主要发现
- MMSA-1在多发性骨髓瘤中特异性表达并与多发性骨髓瘤呈显著正相关。
- MMSA-1表位SLSLLTIYV疫苗在体外诱导明显的CTL反应。
- 多表位肽疫苗负载的树突状细胞诱导的效应T细胞裂解U266细胞较MMSA-1/DKK1单表位疫苗更有效。
- 在骨髓瘤荷瘤重症联合免疫缺陷小鼠中,多表位疫苗较单表位疫苗显著提高生存率,并大幅减小肿瘤体积、减轻骨破坏。
- 多表位疫苗诱导小鼠血中CD4+和CD8+ T细胞频率显著增加,提示其通过改变T细胞亚群和缓解免疫麻痹抑制骨髓瘤生长。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The identification of novel tumour-associated antigens is urgently needed to improve the efficacy of immunotherapy for multiple myeloma (MM). In this study, we identified a membrane protein MMSA-1 (multiple myeloma special antigen-1) that was specifically expressed in MM and exhibited significantly positive correlation with MM. We then identified HLA-A*0201-restricted MMSA-1 epitopes and tested their cytotoxic T lymphocyte (CTL) response. The MMSA-1 epitope SLSLLTIYV vaccine was shown to induce an obvious CTL response in vitro. To improve the immunotherapy, we constructed a multi-epitope peptide vaccine by combining epitopes derived from MMSA-1 and Dickkopf-1 (DKK1). The effector T cells induced by multi-epitope peptide vaccine-loaded dendritic cells lysed U266 cells more effectively than MMSA-1/DKK1 single-epitope vaccine. In myeloma-bearing severe combined immunodeficient mice, the multi-epitope vaccine improved the survival rate significantly compared with single-epitope vaccine. Consistently, multi-epitope vaccine decreased the tumour volume greatly and alleviated bone destruction. The frequencies of CD4+ and CD8+ T cells was significantly increased in mouse blood induced by the multi-epitope vaccine, indicating that it inhibits myeloma growth by changing T cell subsets and alleviating immune paralysis. This study identified a novel peptide from MMSA-1 and the multi-epitope vaccine will be used to establish appropriate individualized therapy for MM.
引用
- Lu C, Meng S, Jin Y, et al. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy. Br J Haematol. 2017. PMID: 28508448. doi:10.1111/bjh.14686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。